Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Balancing open source stem cell science with commercialization

Nature Biotechnology volume 29, pages 115–116 (2011)Cite this article

Subjects

To the Editor:

The United Kingdom took an early lead in establishing regulations for research on human embryonic stem cells (hESCs) in a way that clearly serves the needs of the research community. However, the needs of those who will translate the basic research into therapies are not always aligned with those of basic researchers. In the United Kingdom, this has led to a paradoxical situation in which the regulations that favor basic research are restricting commercial investment.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Tait, J. Technol. Anal. Strategic Management 19, 257–277 (2007).

    Article  Google Scholar 

  2. Chataway, J., Tait, J. & Wield, D. Technol. Anal. Strategic Management 18, 1–17 (2006).

    Article  Google Scholar 

  3. Faulkner, A., Geesink, I., Kent, J. & Fitzpatrick, D. Br. Med. J. 326, 1159–1160 (2003).

    Article  Google Scholar 

  4. European Commission. Off. J. Eur. Union L324, 121–137 (2007).

  5. US Food and Drug Administration. Code of Federal Regulations. Good Tissue Practice for Blood and Biologics Companies. Title 21, Vol. 8. (21 CFR 1271) (FDA, Washington, DC, USA, 1 April 2009). <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1271&showFR=1&subpartNode=21:8.0.1.5.52.3>

  6. Bergman, K. & Graff, G.D. Nat. Biotechnol. 25, 419–424 (2007).

    Article  CAS  Google Scholar 

  7. Anonymous. Nature 460, 933 (2009).

Download references

Acknowledgements

Funding from the UK Economic and Social Research Council for the Innogen Centre (G.L. and J.T.) is acknowledged.

Author information

Authors and Affiliations

  1. Roslin Cells Ltd., Roslin, Midlothian, UK

    Aidan Courtney & Paul de Sousa

  2. School of Law, University of Edinburgh, Edinburgh, UK

    Carol George & Graeme Laurie

  3. Innogen Centre, University of Edinburgh, Edinburgh, UK

    Joyce Tait

Authors
  1. Aidan Courtney
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul de Sousa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carol George
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Graeme Laurie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joyce Tait
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joyce Tait.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Courtney, A., de Sousa, P., George, C. et al. Balancing open source stem cell science with commercialization. Nat Biotechnol 29, 115–116 (2011). https://doi.org/10.1038/nbt.1773

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1773

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing